Article

Baseline WT1-specific immunity and immune responses to WT1-targeted immunotherapy in pediatric patients with malignant solid tumors at high risk for relapse: results from a biomarker-driven multicenter translational phase II clinical trial

2026-07-14

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Biomarkers useful for identifying pediatric patients likely to achieve durable clinical outcomes from Wilms tumor gene 1 (WT1)-targeted cancer immunotherapy (WT1-targeted CIT) and for predicting such outcomes have not been identified. <bold>Methods</bold> A phase II clinical trial of WT1-targeted CIT was conducted. Patients underwent repeated WT1 <sub>235</...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a175de88-0e0c-511c-9518-c142c0fdb649
DOI: 10.21203/rs.3.rs-10301496/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Baseline WT1-specific immunity and immune responses to WT1-targeted immunotherapy in pediatric patients with malignant solid tumors at high risk for relapse: results from a biomarker-driven multicenter translational phase II clinical trialDOI 10.21203/rs.3.rs-10301496/v1Read

Systems-level immunomonitoring in children with solid tumors to enable precision medicineSemantic proximity Read

The Immune landscape of pediatric solid tumorsSemantic proximity Read

Understanding CD8+ T‐cell responses toward the native and alternate HLA‐A∗02:01‐restricted WT1 epitopeSemantic proximity Read

Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II AllelesSemantic proximity Read

Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapySemantic proximity Read

Spontaneous high clonal expansion of Wilms’ tumor gene 1 (WT1)-specific cytotoxic T-lymphocytes in patients with WT1-expressing solid tumorSemantic proximity Read

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevanceSemantic proximity Read

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors: A Systematic Review and Meta-AnalysisSemantic proximity Read

“Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone MarrowSemantic proximity Read

Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R⍺2-targeting CAR T cells: an interim analysisSemantic proximity Read

The T cell receptor landscape of childhood brain tumorsSemantic proximity Read

Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targetsSemantic proximity Read